TITLE

Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine

AUTHOR(S)
Cassano, P.; Soares, C. N.; Cohen, L. S.; Lyster, A. K.; Fava, M.
PUB. DATE
July 2004
SOURCE
Archives of Women's Mental Health;2004, Vol. 7 Issue 3, p167
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To examine sex- and age-related differences of treatment outcome in a cohort of outpatients with major depressive disorder (MDD), with and without comorbid anxiety, treated with fluoxetine. Methods: Outpatients with a SCID-diagnosis of MDD aged 18 to 65 years were treated openly with fluoxetine (20 mg=day) for 8 weeks. The 17-item Hamilton Depression Rating Scale (HAM-D-17) was administered at baseline, and at weeks 2, 4, 6 and 8. Remission of MDD was defined as a HAM-D-17 score =7 at week 8. Rates of remission and change of depressive symptoms of MDD were compared among women aged <45 years and =45 years. The analyses were then repeated in men. The presence of comorbid anxiety disorders was included in the prediction model for change of depressive symptoms of MDD across age and sex. Results: 176 women and 153 men were included in this analysis. Remission of MDD occurred in 57.1% and 50% of younger and older women respectively. Similar rates were present in men (57.2% and 49.1%, respectively). Age did not predict remission of depression or change of depressive symptoms of MDD, in both women and men. Anxious and non-anxious subtypes of depression did not present sex- or age-related differences in treatment outcome. Conclusion: In this cohort of outpatients with MDD, we observed no sex-or age-related differences in response to an 8-week treatment with the SSRI fluoxetine. Similarly, there were no age-related differences among women with anxious and non-anxious subtype of depression.
ACCESSION #
14672118

 

Related Articles

  • Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine. Kobayashi, Katsunori; Ikeda, Yumiko; Suzuki, Hidenori // Molecular Brain;2011, Vol. 4 Issue 1, p12 

    Background: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat mood and anxiety disorders. However, neuronal bases for both beneficial and adverse effects of SSRIs remain poorly understood. We have recently shown that the SSRI fluoxetine can reverse the state of maturation...

  • Fluoxetine effect on kidney water reabsorption. Zenaide Providello Moyses; Fausto Kigui Nakandakari; Antonio José Magaldi // Nephrology Dialysis Transplantation;Apr2008, Vol. 23 Issue 4, p1173 

    Background. The pathogenesis of hyponatraemia caused by fluoxetine(Fx) use in the treatment of depression is not well understood. It has been attributed to a SIADH, although ADH-enhanced plasma level has not yet been demonstrated in all the cases reported in humans. This experiment aimed at...

  • Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites. Matsuzawa-Yanagida, Kiyomi; Narita, Minoru; Nakajima, Mayumi; Kuzumaki, Naoko; Niikura, Keiichi; Nozaki, Hiroyuki; Takagi, Tomoe; Tamai, Eiko; Hareyama, Nana; Terada, Mioko; Yamazaki, Mitsuaki; Suzuki, Tsutomu // Neuropsychopharmacology;Aug2008, Vol. 33 Issue 9, p1952 

    Clinically, it is well known that chronic pain induces depression, anxiety, and a reduced quality of life. There have been many reports on the relationship between pain and emotion. We previously reported that chronic pain induced anxiety with changes in opioidergic function in the central...

  • Depression and Antidepressants. Sajid, Ayesha; Poor, Maria C.; Diaz, David R. // Annals of Psychotherapy & Integrative Health;Summer2011, Vol. 14 Issue 2, p60 

    The article offers information on antidepressants and their effects on depression. It states that antidepressants should be relative to a person's age, lifestyle, and physical condition, for it to be beneficial and effective. The most standard form is said to be the selective serotonin reuptake...

  • Managing the Patient with Co-Morbid Depression and an Anxiety Disorder. Schoevers, Robert A.; Van, Henricus L.; Koppelmans, Vincent; Kool, Simone; Dekker, Jack J. // Drugs;2008, Vol. 68 Issue 12, p1621 

    Depression and anxiety disorders frequently co-occur. This type of co-morbidity is associated with higher severity, suicidality, chronicity and treatment resistance. However, available treatment guidelines mainly focus on treatment for singular disorders. The current paper describes diagnostic...

  • The Evidence for 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression. Altamura, A.C.; Montgomery, S.A.; Wernicke, J.F. // British Journal of Psychiatry;Sep88 Supplement, p109 

    The article reports on the use of fluoxetine in the treatment of depression. Fluoxetine, a selective serotonin-uptake inhibitor, has been established to be effective in the treatment of depression. Various studies have posited that this compound is more effective than placebo. This drug has also...

  • Adding Supplement to SSRI Could Increase Response.  // Psychiatric Annals;Jun2004, Vol. 34 Issue 6, p432 

    The article reports on the effect of the dietary supplement S-adenosylmethionine on the efficacy of antidepressants according to a study from Massachusetts General Hospital. The addition of S-adenosylmethionine supplement has boosted the effects of selective serotonin reuptake inhibitor for...

  • Prescribing for depression. Newson, Louise // GP: General Practitioner;4/21/2006, p50 

    The article focuses on the treatment of depression. Depression is considered to be a common and debilitating condition. According to meta-analysis, Selective Serotonin Reuptake Inhibitors (SSRIs) and low-dose tricyclic antidepressants are effective in treating depression in primary care. This is...

  • Nefazodone and Venlafaxine: Two New Agents for the Treatment of Depression. Goldberg, Richard J. // Journal of Family Practice;Dec1995, Vol. 41 Issue 6, p591 

    This article discusses the basic pharmacology of nefazodone and venlafaxine as antidepressants. Depression is a significant problem in the U.S. There are approximately 13 million people in the U.S. who are depressed but not receiving treatment. Of those who are receiving medication, more than...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics